Nucl Med Mol Imaging.  2019 Aug;53(4):296-299. 10.1007/s13139-019-00597-8.

¹⁸F-FDG PET/MR Refines Evaluation in Newly Diagnosed Metastatic Urethral Adenocarcinoma

Affiliations
  • 1Department of Biomedical and Dental Sciences and of Morpho-functional Imaging, Nuclear Medicine Unit, University of Messina, Messina, Italy. riclaudi@hotmail.it
  • 2Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, Stanford, USA.
  • 3Department of Radiology, Stanford University, Stanford, USA.

Abstract

We described the clinical impact of ¹â¸F-FDG PET/MR in refining the evaluation of a 39-year-old female with newly diagnosed metastatic urethral adenocarcinoma.We detailed the diagnostic imaging workup focusing our attention on the CT, MR, and ¹â¸F-FDG PET/MR different findings. In this case, ¹â¸F-FDG PET/MR imaging evaluation resulted not only effective but also altered staging and spared additional invasive procedures in the assessment of a metastatic urethral adenocarcinoma. Combining a highly sensitive PET with the increase tissue resolution of MR (PET/MR) may improve abdominal and pelvic lesion detection outperforming PET/CT for this indication.

Keyword

Urethral adenocarcinoma; ¹⁸F-FDG; PET/MR; PET/CT; MR; CT

MeSH Terms

Adenocarcinoma*
Adult
Diagnostic Imaging
Female
Humans
Positron-Emission Tomography and Computed Tomography
Full Text Links
  • NMMI
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
    DB Error: unknown error